Chinso Pharmaceutical-B (Stock Code: 2616) released its interim financial report for the six months ending on June 30, 2024. The report indicates that the company recorded revenue of 254.2 million yuan during the reporting period, a slight decrease from 261.5 million yuan in the same period last year. The net profit for the period was 15.7 million yuan, compared to a loss of 209.2 million yuan in the same period last year, achieving a turnaround from loss to profit. Additionally, the company's R&D expenses decreased from 186.8 million yuan in the same period last year to 66.2 million yuan, primarily due to reduced milestone costs, third-party contract costs, and employee costs. The company's management remains confident in future development, will continue to advance the R&D of innovative pipeline drugs, and maximize the commercial value of existing marketed products.

Chinso Pharmaceutical-B (Stock Code: 2616) released its interim financial report for the six months ending on June 30, 2024. The report indicates that the company recorded revenue of 254.2 million yuan during the reporting period, a slight decrease from 261.5 million yuan in the same period last year. The net profit for the period was 15.7 million yuan, compared to a loss of 209.2 million yuan in the same period last year, achieving a turnaround from loss to profit. Additionally, the company's R&D expenses decreased from 186.8 million yuan in the same period last year to 66.2 million yuan, primarily due to reduced milestone costs, third-party contract costs, and employee costs. The company's management remains confident in future development, will continue to advance the R&D of innovative pipeline drugs, and maximize the commercial value of existing marketed products.